Hold Lifted but No Efficacy Proof Leaves ARD-101 Phase 3 Unfunded Risk

FDA Lifts Clinical Hold on Aardvark's Prader-Willi Syndrome Drug ARD-101

The FDA has lifted its clinical hold on Aardvark Therapeutics' small-molecule drug candidate ARD-101, intended for Prader-Willi syndrome, following a new safety study. The hold was initially placed in May 2026 after "reversible cardiac observations" were detected in healthy volunteers receiving above-therapeutic doses of 1,600 mg twice-daily. A subsequent ECG study in healthy volunteers found no cardiac events at therapeutic doses of 200 mg and 400 mg twice-a-day. Aardvark plans to request a meeting with the FDA to finalize Phase 3 plans and expects to resume clinical activities for ARD-101 in 2027. The prior hold had led to the suspension of other trials and workforce reductions.

• Aardvark Therapeutics voluntarily suspended its Phase 3 HERO and OLE studies for ARD-101 in February 2026 due to "reversible cardiac observations" in healthy volunteers. These signals, indicative of compromised heart efficiency, were detected at above-therapeutic doses of 1,600 mg twice-daily. The FDA subsequently imposed a full clinical hold on the program in May 2026, leading to the unblinding and termination of the trials as originally designed.
• To address the safety concerns, Aardvark conducted an additional thorough ECG study in healthy volunteers. This study revealed no cardiac events when ARD-101 was administered at therapeutic doses of 200 mg and 400 mg twice-a-day. Based on these new safety data, the FDA officially lifted its clinical hold on ARD-101, clearing the path for the drug's continued development.
• With the clinical hold removed, Aardvark Therapeutics intends to meet with the FDA to align on revised Phase 3 plans for ARD-101 and anticipates resuming clinical activities for Prader-Willi syndrome in 2027. The earlier hold had significant business consequences for the biotech, including the pausing of Phase 2 studies for ARD-201 (an obesity asset) and a workforce reduction from 40 employees to 28 by July 2026.

Addressing Cardiac Safety: ARD-101's Path to Clinical Hold Lift

A first-in-human phase 1 randomized, double-blind, placebo-controlled trial evaluated safety, pharmacokinetics, and pharmacodynamics of single or multiple ascending doses of oral ARD-101 at 40, 100, and 240 mg in healthy adults. A total of 43 subjects were randomly assigned and dosed to ARD-101 or placebo with 42 subjects completing the study treatment.

ARD-101 demonstrated a favorable safety profile and was well tolerated at all dose levels. ARD-101 was found to be >99% restricted to the gut with minimal systemic exposure. Blood samples taken 1 hour after administration showed that subjects dosed with 240 mg of ARD-101 had elevated circulating levels of several gut peptide hormones.

Further clinical trials will evaluate ARD-101 in patients with metabolic and inflammatory disorders. The knowledge base does not have sufficient information on this aspect.

Beyond PWS: ARD-101's Broader Therapeutic Potential

The knowledge base does not have sufficient information to answer this question.

Navigating PWS: Unmet Needs Amidst Evolving Therapies

Current treatment for Prader-Willi syndrome (PWS) remains largely supportive, centered on strict environmental control, restricted diet and regular physical exercise, with recombinant human GH treatment dramatically changing phenotype but not resolving core disease drivers. Despite these measures, hyperphagia, severe obesity and multisystem comorbidities persist, and no drugs have proven efficacy in controlling appetite.

• Hyperphagia and obesity are difficult to prevent and maintain: Subjects with PWS will become severely obese unless food intake is strictly controlled, with constant and obsessive food seeking behavior. Prevention of obesity is mandatory from the first years of life, because once obesity develops it is difficult to maintain control of food intake, and successful weight loss and maintenance are hardly accomplished. The only treatment for hyperphagia is environmental control, including locked kitchens and continuous supervision, with caloric intake restricted to prevent obesity, which subsequently increases hunger drive even more.

• Growth hormone therapy requires lifelong adjunct measures and careful monitoring: Restricted diet and regular physical exercise are cornerstone treatments in PWS also during GH treatment, and GH treatment should be continued as long as benefits outweigh risks. Adverse effects are few, but glucose metabolism and changes in respiration must be monitored carefully, especially in individuals with predispositions, with concerns regarding GH-induced insulin resistance leading to discontinuation in reported cases. Obesity and OSA represented contraindications to growth hormone, and GH treatment positively influences body composition, but does not normalize it.

• Exercise implementation is limited by disease physiology: Lower energy expenditure, hypotonia, decreased muscle mass, and cognitive impairment make exercise challenging for this population. Young adults are capable of performing resistance/strength-building exercise, but lower CK and peak lactate levels in PWS may reflect decreased muscle mass, with CK lower in PWS versus controls (62 ± 16 vs. 322 ± 100 U/L, p < .04) and peak lactate 3.7 ± 0.7 in PWS versus 7.3 ± 0.7 mmol/L in controls (p < .001).

• Pharmacologic options show variable efficacy and trial limitations: Combinations of Metformin with differing insulin regimes did not improve glucose levels in a reported adolescent case, and Liraglutide and Metformin did not improve glucose levels nor weight, requiring Liraglutide and Empagliflozin in combination for rapid normalisation. For oxytocin-system approaches, there is currently no convincing evidence that intranasal oxytocin improves symptoms of PWS due to study limitations, and carbetocin nasal spray did not demonstrate efficacy compared with placebo for hyperphagia in the 12-week COMPASS PWS study, with treatment difference of 0.3 (95% confidence interval: -1.8, 2.4; P = 0.79). In CARE-PWS, primary endpoints showed numeric improvements in both HQ-CT and CY-BOCS which were not statistically significant, with enrollment stopped prematurely because of onset of the COVID-19 pandemic.

• High comorbidity burden and caregiver impact constrain care: PWS subjects die prematurely from complications conventionally related to obesity, including diabetes mellitus, metabolic syndrome, sleep apnea, respiratory insufficiency, and cardiovascular disease. Caregivers experienced high caregiver burden with an average ZBI score of 44.4 ± 15.4, with negative impact on romantic relationship, ability to work, sleep, and mood, while individuals with PWS had an average wait of 22 months for an appointment with a psychologist and 4 months for an appointment with a psychiatrist.

ARD-101's Comeback: Reshaping Prader-Willi Syndrome Treatment

The recent lifting of the FDA's clinical hold on Aardvark Therapeutics' ARD-101 for Prader-Willi syndrome (PWS) marks a significant turning point for the company and the PWS community. This decision, following a new safety study that found no cardiac events at therapeutic doses after initial reversible observations at supra-therapeutic levels, allows ARD-101 to resume its development path towards a pivotal Phase 3 trial.

PWS is a complex genetic disorder characterized by profound hyperphagia, often leading to severe obesity and associated health complications. The underlying pathophysiology involves a significant dysregulation of hunger and satiety hormones, including elevated ghrelin and altered responses of GLP-1 and PYY. ARD-101, a potential TAS2R agonist, offers a novel, gut-restricted approach, with preclinical data suggesting reductions in food intake and body weight, and Phase 1 results showing an elevation of circulating gut peptide hormones. This mechanism could directly address the hormonal imbalances central to PWS hyperphagia.

However, the road ahead is not without its challenges.

• Demonstrating Efficacy: While the mechanism is promising, ARD-101 must now prove its clinical efficacy in a larger Phase 3 setting, particularly in improving hyperphagia and weight management, where other agents like GLP-1 receptor agonists have shown mixed results.

• Navigating the Competitive Landscape: The PWS treatment paradigm already includes an FDA-approved therapy, diazoxide choline extended-release (DCCR) tablets, which has demonstrated meaningful benefits for hyperphagia. ARD-101 will need to establish a clear differentiation in terms of efficacy, safety, or patient benefit to secure a strong market position.

• Sustained Safety Vigilance: Despite the resolution of the initial cardiac signal, continued rigorous monitoring for long-term cardiac safety will be paramount, especially given the patient population's inherent cardiovascular risks.

The successful progression of ARD-101 could validate a new therapeutic class targeting gut taste receptors for metabolic disorders, potentially opening avenues for Aardvark beyond PWS. This event not only revitalizes a key program but also underscores the resilience required in developing treatments for rare diseases with complex etiologies.